| Biotechnology Industry | Healthcare Sector | Ms. Jing Wang CEO | XSHE Exchange | CNE1000047P9 ISIN |
| CN Country | 650 Employees | 29 May 2025 Last Dividend | 17 Jun 2022 Last Split | - IPO Date |
Zhejiang Wecome Pharmaceutical Company Limited is a prominent entity in China's pharmaceutical industry, focusing on the integration of traditional Chinese medicine with Western medical practices. Established in the year 2000 and headquartered in Lishui, China, the company has evolved from its former identity as Zhejiang Weikang Pharmaceutical Co., Ltd. to a comprehensive pharmaceutical company. It is engaged in the research, development, manufacture, and sale of a diverse range of pharmaceutical products. In addition to its manufacturing capabilities, Zhejiang Wecome Pharmaceutical extends its services into the distribution sector, including retail chains, to ensure a wide reach of its products across various markets.
These are solid dosage forms in which one or more medicinal ingredients are enclosed within a small shell. They are designed for oral intake and dissolve rapidly in the stomach.
Tablets are compressed or molded dosage forms containing medicinal substances with or without diluents. Zhejiang Wecome Pharmaceutical produces tablets for various therapeutic purposes.
Granules are small, irregular particles of medicinal substances, often prepared for better solubility and absorption. They are suitable for delivering doses that are too large to be made into tablets.
Soft gel capsules encase liquid or semi-solid doses in a gelatin-based shell. They offer an alternative to hard capsules for those who have difficulty swallowing.
Traditional pills, often used in Chinese medicine, are small, round solid doses formed by mixing powdered drug with an excipient and then shaping them. These are designed for slow, sustained release of the medication.
Expanding beyond manufacturing, Zhejiang Wecome also operates a distribution business through retail chains. This includes the dispensing and sale of pharmaceutical products to end consumers, enhancing the availability of its medicines.